Home » Stocks » PTE

PolarityTE, Inc. (PTE)

Stock Price: $1.20 USD 0.23 (23.18%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $1.15 -0.05 (-4.17%) May 11, 7:12 AM
Market Cap 96.71M
Revenue (ttm) 10.13M
Net Income (ttm) -42.85M
Shares Out 38.78M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $1.20
Previous Close $0.97
Change ($) 0.23
Change (%) 23.18%
Day's Open 1.25
Day's Range 1.16 - 1.38
Day's Volume 114,309,478
52-Week Range 0.55 - 2.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on In...

Other stocks mentioned: APOP, CKX, CUE, ELTK, LEDS, OBLN, PRPO ...
18 hours ago - InvestorPlace

PolarityTE (NASDAQ: PTE) shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints. In the company's multi-center randomized controlled...

19 hours ago - Benzinga

These penny stocks just released big news; will they be on your watchlist? The post Best Penny Stocks to Buy?

Other stocks mentioned: CFMS, HRVSF
22 hours ago - PennyStocks

PolarityTE Inc (NASDAQ: PTE) has announced preliminary topline data from a multi-center randomized controlled trial evaluating SkinTE for the treatment of Diabetic Foot Ulcers. The 100-subject trial, wh...

22 hours ago - Benzinga

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced preliminary topline data demonstrating that a multi-center randomized controlled trial evaluating treatment of Diabetic Fo...

23 hours ago - Business Wire

PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended March 31, 2021 by press release on Thursday, May 13, 2021 at approximate...

1 week ago - Business Wire

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Shares of PolarityTE (NASDAQ:PTE) fell 2.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 64.47% over the past year to ($0.27), which missed...

1 month ago - Benzinga

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the fourth quarter...

1 month ago - Business Wire

PolarityTE (NASDAQ:PTE) announces its next round of earnings this Tuesday, March 30. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

1 month ago - Benzinga

PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2020 by press release on Tuesday, March 30, 2021 at approximat...

2 months ago - Business Wire

PolarityTE, Inc. (PTE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwr...

2 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

Other stocks mentioned: RVNC, VIE
2 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, is pleased to provide this update. ...

3 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 16/165,169 fil...

3 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products...

3 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today it has completed target enrollment of 1...

3 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products...

3 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products...

3 months ago - Business Wire

Investors need to pay close attention to PolarityTE (PTE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that the Board of Directors has formed ...

3 months ago - Business Wire

PolarityTE (PTE) stock is soaring higher on Friday as investors prepare for its participation in an upcoming event on Monday. The post PTE Stock Alert: 7 Things for Investors to Know About PolarityTE as...

4 months ago - InvestorPlace

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwr...

4 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products...

4 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) is pleased to report the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Application No. 14/954,335. This is th...

5 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a company focused on transforming the lives of patients by discovering, designing, and developing a range of regenerative tissue products...

5 months ago - Business Wire

PolarityTE, Inc. (PTE) CEO David Seaburg On Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

PolarityTE, Inc.'s (PTE) CEO David Seaburg on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

  Shares of PolarityTE (NASDAQ:PTE) moved higher by 7.3% in pre-market trading after the company reported Q3 results.

6 months ago - Benzinga

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar...

6 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that the Company submitted in Au...

6 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approxim...

6 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and...

7 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institu...

7 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced cost per product data from the protocol-specified interim analysis in the Company’s ongoing randomized controlled trial (R...

7 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that third quarter 2020 revenues will likely meet or exceed top end of the previous guided range of $2.7M to $3.2M.

7 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C.

8 months ago - Business Wire

PolarityTE, Inc. (PTE) CEO David Seaburg on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calenda...

9 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors.

9 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approxi...

9 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized contr...

9 months ago - Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled t...

9 months ago - Business Wire

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: AVGR, CSV, MOGO, TNK
11 months ago - Zacks Investment Research

It is possible that the markets have run too far making today ideal for taking a few short positions. According to our deep learning algorithms, these are the ones to go after.

Other stocks mentioned: BPT, DVN, HAL, LVS
11 months ago - Forbes

PolarityTE's (PTE) CEO David Seaburg on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of PolarityTE (NASDAQ:PTE) were flat in pre-market trading after the company reported Q1 results.

11 months ago - Benzinga

About PTE

PolarityTE, Inc., a biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates through two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or remova... [Read more...]

Industry
Biotechnology
IPO Date
Aug 13, 1999
CEO
Denver Lough
Employees
80
Stock Exchange
NASDAQ
Ticker Symbol
PTE
Full Company Profile

Financial Performance

In 2020, PolarityTE's revenue was $10.13 million, an increase of 79.16% compared to the previous year's $5.65 million. Losses were -$42.85 million, -53.67% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PolarityTE stock is "Buy." The 12-month stock price forecast is 3.00, which is an increase of 150.00% from the latest price.

Price Target
$3.00
(150.00% upside)
Analyst Consensus: Buy